NICE (UK National Institute for Clinical Excellence) refuses routine use of ACT (autologous cartilage transplantation)
This article was originally published in Clinica
The UK National Health Service (NHS) will not offer autologous cartilage transplantation (ACT) for routine primary care treatment of articular cartilage defects of the knee. Guidance issued by the National Institute for Clinical Excellence (NICE) recommends that ACT should be performed only as part of a clinical trial or, in exceptional circumstances, at centres where clinical trials are taking place and other treatments have failed.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.